iOnctura CEO to Present at the J.P. Morgan Healthcare Conference
iOnctura, a pioneering clinical-stage biopharmaceutical company focused on developing precision oral small molecules for challenging cancers, is set to have its Chief Executive Officer, Catherine Pickering, present at the esteemed J.P. Morgan Healthcare Conference. This event, known for its significant role in drawing attention to the most promising innovations in healthcare, will take place soon in San Francisco.
On the agenda, Dr. Pickering, during her presentation on January 15, will delve into the details of iOnctura's advancements, notably the progress of their lead therapeutic candidate, roginolisib. This first-of-its-kind allosteric modulator of PI3K? represents the forefront of precision oncology, aiming to provide new hope for patients battling various cancers.
The J.P. Morgan Healthcare Conference is recognized globally as the largest and most prominent forum for healthcare investment. The gathering not only showcases innovative companies but also acts as a platform for capital formation, connecting investors with emerging technologies. iOnctura's presence at this event highlights the accelerating interest in its approach to precision oncology and the promising advances it has made.
"We are ecstatic to be sharing our journey and insights at this prestigious conference," said Catherine Pickering, CEO and co-founder of iOnctura. "The recognition underscores the increasing excitement around our scientific pursuits and the clinical milestones we’ve achieved with roginolisib. Engaging with dedicated partners at this event is a fantastic opportunity to discuss our vision for transforming cancer treatment."
The management team at iOnctura will also be available for intimate discussions with investors and potential collaborators throughout the conference. This approach accentuates their commitment to not only advancing science but also building strong partnerships that can further drive their mission.
Beyond the conference, iOnctura is actively revolutionizing cancer treatment through its innovative pipeline. The company is committed to targeting neglected and difficult cancers, a mission they pursue with a portfolio of first-in-class small molecules.
Lead candidate, roginolisib, is particularly noteworthy due to its unique method of action. It operates without the common drawbacks associated with previous therapies, promising improved tolerability while effectively inhibiting PI3K?, a crucial pathway in the development of various malignancies.
iOnctura's innovative approach has garnered attention not only for its potential efficacy but also for the compassionate vision behind it—extending life expectancy and enhancing health for patients and their families facing the challenges of cancer.
Roginolisib has already demonstrated promising outcomes in early clinical evaluations. Positive signals were observed in Phase I trials exploring its safety and preliminary efficacy in treating solid tumors and hematological cancers. Notably, the responses in uveal melanoma indicated a significant increase in overall survival rates compared to historical benchmarks.
The ongoing clinical trials are pivotal as they explore multiple indications. The Phase II OCULE-01 study focusing on uveal melanoma started in March 2025, while the PULMO-01 study for non-small cell lung cancer (NSCLC) commenced in May 2025. Additionally, the HEMA-MED Phase I/II study in myelofibrosis is well underway after starting in late 2025.
iOnctura operates with an invigorated focus on ensuring the successful development and commercialization of therapies that positively impact lives. Its global footprint includes a headquarters in Amsterdam, with supporting branches in Geneva and Cambridge, driven by a passionate team committed to redefining what's possible in precision oncology.
The support from notable institutional investors highlights the strong belief in iOnctura's vision. Their commitment to innovation not only reflects in the financial backing but also in the collective effort to propel the company's mission forward.
Frequently Asked Questions
What is iOnctura's main area of focus?
iOnctura primarily specializes in developing precision oral small molecules aimed at treating neglected and hard-to-treat cancers.
Who will be presenting at the J.P. Morgan Healthcare Conference?
Catherine Pickering, CEO of iOnctura, will be representing the company at this prestigious event.
What is roginolisib?
Roginolisib is iOnctura's lead candidate, a first-in-class allosteric modulator of PI3K? designed to offer effective cancer treatment with improved tolerability.
When is the J.P. Morgan Healthcare Conference?
The conference is scheduled to take place from January 12–15, 2026.
Where is iOnctura headquartered?
iOnctura is headquartered in Amsterdam, with additional facilities in Geneva and Cambridge.
